Date: March 6, 2025
Source: The Hill
In a game-changing ruling, a federal judge in Texas has stopped compounding pharmacies from making affordable versions of Eli Lilly’s blockbuster weight loss drugs, Zepbound and Mounjaro. On March 5, 2025, Judge Mark Pittman upheld the FDA’s call that tirzepatide, the active ingredient in these GLP-1 drugs, is no longer in shortage. This ends a practice that let compounders offer lower-cost alternatives to these sought-after diabetes and obesity treatments.
For medspas, this is big news. Compounded drugs—cheaper than branded versions—were a go-to for many offering weight loss treatments. Now, smaller pharmacies must stop production immediately, and larger FDA-regulated outsourcing facilities have until March 19, 2025, to wind down. The decision came after the Outsourcing Facilities Association (OFA) sued the FDA, claiming the agency’s move jacked up drug prices and hurt patient access. Eli Lilly, meanwhile, cheered the ruling, slamming unapproved copies as risky.
What’s next? Medspa owners may face higher costs for branded drugs, potentially reshaping client care and pricing. A similar fight over semaglutide is still in play, so stay tuned. This shift could push medspas to rethink how they deliver these trending anti-obesity solutions.
Sorting Fact from Fiscal Fear: What the New Pharma Tariff Really Means for Your Medspa
Social media buzzing about a 100% pharma tariff? Get the real facts on how new import taxes will impact your Medspa’s Botox, injectables, and pricing. Separate fear from reality.
White Hats, Buckle Up: A Response to ELLE’s Med Spa Exposé
ELLE’s investigation hits real issues—counterfeits, credentials, and thin oversight. Here’s the part headlines skip: how ethical med spas prove authenticity, competency, and cold-chain safety in plain sight—and what patients should ask for every time.
Rhode Island Medical Spa Laws 2025: New Safety Act Requirements for Practice Owners
New legislation establishes mandatory facility licensing and enhanced supervision protocols for all Rhode Island medical spas - EFFECTIVE IMMEDIATELY! Rhode Island medical spa owners face significant regulatory changes following Governor Daniel McKee's signing of the...
AmSpa Names 25 Distinguished Women in Medical Aesthetics 2025: Industry Leaders Recognized at WALC Conference
News provided by American Med Spa Association, LLC Aug 06, 2025, 09:00 ETThe American Med Spa Association (AmSpa) has unveiled its prestigious list of Distinguished Women in Medical Aesthetics 2025, honoring 25 exceptional leaders who exemplify excellence,...
Obagi’s Skin Empire Just Bought Its Way Into Injectables — What That Means for Medspas
Obagi Medical enters U.S. dermal filler market with Saypha® ChIQ™ and MagIQ™ HA injectables following acquisition of Novaestiq Corp.
The Florida “Shedspa” Story: Let’s Call This What It Really Is
A Florida woman was arrested for operating an unlicensed “medspa” in her backyard shed, causing facial paralysis in a patient. But calling this a medspa story misses the real issue: legitimate-looking practices that cut corners on sourcing while hiding in plain sight. The industry needs real oversight to protect compliant medspas from being lumped in with backyard operations.